Diagonal Bio’s CEO Karin Wehlin increases ownership
Non-regulatory
Diagonal Bio AB’s (”Diagonal Bio” or the ”Company”) CEO, Karin Wehlin, has directly and through Wehlin’s fully owned company WW Advise AB purchased 8,500,000 shares in the Company to a total price of approximately SEK 170,000 (average price SEK 0.02 per share). The acquisition has been made in the market during 11-12 February 2025.
Diagonal Bio AB’s rights issue of units oversubscribed
Regulatory
The subscription period in Diagonal Bio AB’s (“Diagonal Bio” or the “Company”) rights issue of units of initially approximately SEK 6.0 million ended on 6 February 2025 (the “Rights Issue”). The Rights Issue was subscribed to a total of approximately 122 percent, including subscription undertakings, meaning that no underwriting commitments have been utilized. In parallel with the Rights Issue, the Company has carried out the directed issue of units which was announced on 23 December 2024 and approved by the Extraordinary General Meeting 17 January 2025, of initially approximately SEK 1.7 million to Redén Trotting AB and Svea Bank AB (the “Directed Issue”). In total, through the Rights Issue and the Directed Issue, Diagonal Bio is thus provided proceeds of approximately SEK 7.7 million before deduction of issue related costs. Should all attached warrants of series TO 2 issued in the Rights Issue and the Directed Issue be exercised, the Company may receive additional proceeds of approximately SEK 3.4 million in June 2025.
Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) has signed an agreement with Stall Goop regarding a pilot test of LAMPlify®. The three-month pilot test, starting in February 2025, aims to enhance equine health and performance by enabling early detection of potential virus infections in horses.
Diagonal Bio announces positive pilot test results and secures order from StallZet
Regulatory
Diagonal Bio AB (publ) (“Diagonal Bio” or the “Company”) announces an order valued at approximately SEK 150,000 from Daniel Redén, a renowned horse trainer at StallZet. The order comes as a result of the successful completion of the pilot test which started in October 2024 and includes the purchase of LAMPlify® along with associated consumables.
The subscription period of Diagonal Bio AB’s rights issue of units commences today
Regulatory
Today, 23 January 2025, the subscription period in Diagonal Bio AB’s (“Diagonal Bio” or the “Company”) rights issue of units of initially approximately SEK 6 million, with preferential rights for the Company’s existing shareholders, commences (the “Rights Issue”). The subscription period runs until 6 February 2025. The Rights Issue was resolved upon by the Board of Directors on 23 December 2024 and approved by the Extraordinary General Meeting on 17 January 2025, together with the resolution on a directed issue of units (the “Directed Issue”, together, the Rights Issue and the Directed Issue are referred to as the “Transaction”). The purpose of the Transaction is to provide funds to focus on validation of LAMPlify®’s commercial interest. The Rights Issue is covered by subscription undertakings from the Board members, the CEO, and other shareholders, of in total approximately SEK 0.4 million, corresponding to approximately 6 percent of the Rights Issue. In addition, Diagonal Bio has received underwriting commitments from the Company’s CEO Karin Wehlin, the Board members and a number of external investors of a total of SEK approximately 3 million, corresponding to approximately 50 percent of the Rights Issue, which means that the Rights Issue in total is covered by subscription and underwriting commitments of 56 percent. The Board members and CEO Karin Wehlin have entered into customary lock-up agreements corresponding to 100 percent of their respective shareholdings until 31 July 2025.
We may request cookies to be set on your device. We use cookies to let us know how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
Other external services
We use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.